Did You Know...
...that when IBM conducted a market study of Chester Carlson's invention in 1959, the company concluded that it would take only 5000 units of his new product to saturate the market? IBM therefore declined to be part of the new product introduction. Too bad for IBM. Carlson's invention was the xerography process, and his new product was the beginning of the Xerox Corporation. It is estimated that every day, worldwide, 3,000,000,000 copies are made!!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7439037 | Use of aminoglycoside resistance gene Use of aminoglycoside resistance gene product for achieving high-density growth of animal cells. ... | 10/21/2008 |
| 7387873 | Human myeloma cell line There is provided a human myeloma cell tine for use in a method for producing a human monoclonal antibody. ... | 06/17/2008 |
| 7267965 | Means and methods for regulating gene expression The invention relates to means and methods for regulating gene expression and production of proteinaceous molecules. The invention provides a method for producing a proteinaceous molecule in a cell comprising selecting a cell for its suitability for producing the pr... | 09/11/2007 |
| 7238525 | Strategy for leukemia therapy The chimeric Bcr-Abl oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). In the cytoplasm, the protein transduces a growth signal that is responsible for overexpansion of cells. In the nucleus, the protein induces apoptosis. The invention is... | 07/03/2007 |
| 7220559 | Development of human monoclonal antibodies and uses thereof This invention provides: a heteromyeloma, other than B6B11, capable of producing a trioma when fused with a human lymphoid cell, wherein the trioma is capable of producing a monoclonal antibody-secreting tetroma when fused with a second, antibody-secreting human lym... | 05/22/2007 |
| 7166445 | Methods and host cells for improved cell culture The invention provides improved methods of recombinant protein production in cell culture. More specifically, the invention relates to the modulation of the IGF-1 signaling pathway in cells so as to improve production characteristics. ... | 01/23/2007 |
| 7160723 | Cell separation compositions and methods The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover even rare cell types in high yield. ... | 01/09/2007 |
| 7132288 | Medium for culturing tumor cells Disclosed is a medium for cultivating tumor cells, comprising the following constituents, as comprised for example in the medium RPMI 1640: (a) fetal calf serum (FCS), (b) penicillin-streptomycin, (c) L-glutamine, (d) transferrin, (e) insulin, (f) human epidermal gr... | 11/07/2006 |
| 7063964 | Nucleic acids encoding IL-12 antibody The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, metho... | 06/20/2006 |
| 7060267 | MASP-2, a complement-fixing enzyme, and uses for it The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway. ... | 06/13/2006 |
| 7049072 | Gene expression analysis of pluri-differentiated mesenchymal progenitor cells and methods for diagnosing a leukemic disease state Pluri-differentiated human mesenchymal progenitor cells (MPCs) are isolated. A method isolates and purifies human mesenchymal progenitor cells from Dexter-type cultures for characterization of and uses, particularly therapeutic uses for such cells. Specifically, iso... | 05/23/2006 |
| 7041438 | Use of human embryonic stem cells for drug screening and toxicity testing This disclosure provides an improved system for culturing human pluripotent stem (pPS) cells in the absence of feeder cells. The role of the feeder cells can be replaced by supporting the culture on an extracellular matrix, and culturing the cells in a conditioned m... | 05/09/2006 |
| 7026132 | Method of monitoring the effect of Cathepsin S inhibitors The present invention relates to a method for monitoring the effect of in vivo administration of Cathepsin S inhibitors by measuring accumulation of an intermediate degradation product of invariant chain (Ii), in particular the p10 Ii fragment, in blood of dosed sub... | 04/11/2006 |
| 6969601 | MASP-2, a complement-fixing enzyme, and uses for it The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway. ... | 11/29/2005 |
| 6969609 | Recombinant vector expressing multiple costimulatory molecules and uses thereof The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect... | 11/29/2005 |
| 6933148 | Cell separation compositions and methods The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover even rare cell types in high yield. ... | 08/23/2005 |
| 6872567 | Method for separating cells using immunorosettes The present invention relates to methods for separating cells using immunorosettes. The method involves contacting a sample containing nucleated cells and red blood cells with an antibody composition which allows immunorosettes of the nucleated cells and the red blo... | 03/29/2005 |
| 6864047 | IL1-β: a new target for myeloma therapy Diagnostic methods for the detection of multiple myeloma (MM) and the identification of high-risk patients with multiple myeloma-related plasma proliferative disorders, such as MGUS or SMM, likely to progress to active MM are described. The diagnosis is based on the... | 03/08/2005 |
| 6838282 | Antibody recognizing a small subset of human hematopoietic cells The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. I... | 01/04/2005 |
| 6835566 | Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses A method for obtaining lineage committed human cells imbued with enhanced proliferative potential, biological function, or both, comprising culturing lineage committed human cells under physiologically acceptable liquid culture conditions, where the liquid culture m... | 12/28/2004 |
| 6825324 | Antibodies to receptor protein tyrosine kinases The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein... | 11/30/2004 |
| 6812023 | Methods of producing membrane vesicles The present invention relates to methods of preparing biological material, for use in various experimental, diagnostic or therapeutic uses, including immunotherapy treatment or prophylaxy of tumors. More particularly, the present invention relates to methods of prep... | 11/02/2004 |
| 6677156 | Non-adenoviral gene product-based complementing cells for adenoviral vectors The invention provides cells and methods of using the cells for the propagation of replication-deficient adenoviral vectors. The cells comprise at least one heterologous nucleic acid sequence which upon expression produces at least one non-adenoviral gene... | 01/13/2004 |
| 6632608 | Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity The invention demonstrates that the transcription factor XBP-1 is a regulator of hepatocyte growth, plasma cell differentiation and T cell subset activity. Methods for identifying modulators of hepatocyte growth, plasma cell differentiation and/or T cell ... | 10/14/2003 |
| 6632832 | Anti-cancer activity of carvedilol and its isomers The present invention provides for pharmaceutical compositions comprising carvedilol for treatment of cancer. More particularly the invention relates to the use of carvedilol for treatment of cancers of the colon, ovary, breast, prostate, pancreas, lung, ... | 10/14/2003 |
| 6616925 | Combined preparation for the treatment of neoplasic diseases or of infectious diseases The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, ... | 09/09/2003 |
| 6602709 | Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells This invention relates to methods and compositions useful for delivering antigens to dendritic cells which are then useful for inducing antigen-specific cytotoxic T lymphocytes and T helper cells. This invention also provides assays for evaluating the act... | 08/05/2003 |
| 6555372 | Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides A composition for enhancing immunogenicity of tumor cells or pathogen-infected cells comprising a compound having an -glycosylceramide structure or a salt or solvate thereof is provided. Tumor cells of which immunogenicity is enhanced by the compou... | 04/29/2003 |
| 6540994 | Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-7 is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity... | 04/01/2003 |
| 6465251 | Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin We teach a strategy to obtain large quantities of desired APCs, activated B cells, which are superior in their capacity to present tumor protein antigen in a multiadministration protocol. Human B cells can be obtained from peripheral blood in large number... | 10/15/2002 |
| 6448075 | Method for separating cells using immunorosettes The present invention relates to methods for separating cells using immunorosettes. The method involves contacting a sample containing nucleated cells and red blood cells with an antibody composition which allows immunorosettes of the nucleated cells and ... | 09/10/2002 |
| 6361997 | Genetically modified CD34-negative adherently growing stem cells and their use in gene therapy The invention relates to the use of genetically modified, very early haematopoietic and mesenchymal stem cells (negative for the expression of the surface molecule CD34) in the individual gene therapy of mono- or oligogenetic diseases or in cell therapy. ... | 03/26/2002 |
| 6355410 | Method of reducing cell proliferation by inhibiting the Na+/H+ exchanger and inducing apoptosis The Na+ /H+ exchanger isoform 1 (NHE-1) is primarily responsible for the regulation of the intracellular pH (pHi). It is a ubiquitous amiloride-sensitive growth factor activatable exchanger. There is a direct correlation b... | 03/12/2002 |
| 6348344 | Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same Bacterial, yeast and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active hepar... | 02/19/2002 |
| 6338845 | Tumor killing effects of enterotoxins, superantigens, and related compounds Superantigens, including staphylococcal enterotoxins, are useful agents for killing tumor cells, enhancing antitumor immunity and treating cancer in a tumor-bearing host. Other useful superantigens include Streptococcal pyrogenic exotoxin, toxic shock syn... | 01/15/2002 |
| 6316227 | Nucleic acids encoding interleukin-5 specific recombinant antibodies An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.... | 11/13/2001 |
| 6297052 | B cell culture system comprising high density membrane bound CD40 ligand The present invention provides methods of proliferating B cells as a means of obtaining large numbers of B cells. The present invention further provides methods of differentiating a proliferating B cell population to antibody producing cells.... | 10/02/2001 |
| 6214333 | Vasoprotective recombinant adenovirus vector containing a human TFPI gene A recombinant adenoviral vector encoding the human tissue factor pathway inhibitor (TFPI) gene is disclosed which is useful for transduction of vascular smooth muscle cells at a selected blood vessel site to provide local vascular expression of TFPI. A me... | 04/10/2001 |
| 6165715 | Expression systems The invention relates to new expression systems and in particular to an expression system in which a gene of interest is expressed at an optimal level. The invention provides a recombinant expression vector comprising a gene of interest and a selectable m... | 12/26/2000 |
| 6083725 | Tranfected human cells expressing human -galactosidase A protein A therepeutic method whereby an individual suspected of having an -galactosidase A deficiency, such as Fabry disease, is treated either with (1) human cells that have been genetically modified to overexpress and secrete human -gal A, or (2) ... | 07/04/2000 |
